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ABSTRACT 
In recent years, cancer treatments have progressed substantially. However, the tumor 
microenvironment is dynamic and continuously evolving thereby resulting in decreased efficacy 
to therapies, and resistant cancer cells. The development of drug resistance in cancer patients 
may potentially trigger or instigate disease progression in the presence of therapeutic 
interventions. In this study, we investigated effects of chronic Gefitinib treatments in a lung 
cancer cell line model. Gefitinib is a tyrosine kinase inhibitor targeting specific mutations within 
the epidermal growth factor receptor (EGFR). Lung cancer cells treated for extended periods of 
time with Gefitinib displayed resistant phenotypes, typically characterized by DNA damage, 
epithelial- mesenchymal transition (EMT) as well as heightened and sustained levels of reactive 
oxygen species (ROS). Furthermore, we uncovered novel cancer resistant phenotypes, namely 
dysregulated mitochondrial biogenesis, endoplasmic reticulum (ER) alterations, cellular calcium 
levels and propensity towards bypassing senescence.  
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1 INTRODUCTION 
Cancer results in the death of approximately half a million people a year, in the United 
States alone (1). A ravaging disease marked by genetic mutations and aberrant growth, cancer 
appeared to be a death sentence, but in recent years has become a treatable chronic disease. The 
standard of treatment for cancer has evolved substantially since initial therapies that utilized 
mustard gas derivatives and antifolates (2). These therapies functioned by suppressing the over 
proliferative nature of cancer cells which is similar to the mechanism of traditional 
chemotherapies. However, newer therapies (known as targeted or precision-based treatments) 
function by direct targeting of specific, gene aberrations that instigate or promote tumor 
development and progression (2). Selective adaptations within a subset of cancer cells contribute 
to unresponsiveness to previously effective therapies, a phenomenon termed drug resistance. As 
would be expected, drug resistance contributes to treatment failure, cancer progression, and 
ultimately increased cancer-related mortality. 
One such targeted therapy is Gefitinib (Iressa), a tyrosine kinase inhibitor that targets 
EGFR mutations in certain non-small cell lung cancers (NSCLC) thereby acting as an antagonist 
against EGFR activation. The therapeutic effects of Gefitinib typically benefit individuals who 
possess an EGFR in-frame exon 19 deletion (DelE746-A750) (3). However, chronic exposure to 
Gefitinib may result in secondary effects that trigger or correlate with the development of drug 
resistance and cancer progression. A classic example of drug resistant phenotype is the epithelial 
to mesenchymal transition (EMT), which is also a hallmark of cancer progression. EMT marks 
the loss of cancer cell adhesion and the beginning of increased cellular motility and invasive 
cancer. The expression shift of EMT genes is strongly associated with resistant and progressive 
cancer phenotypes. A previous microarray identified alterations of select EMT genes of interest 
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with regards to Gefitinib resistance. Down-regulated expression of E-cadherin and Keratin-19 
(epithelial markers) corresponded with striking upregulation of mesenchymal markers, such as 
Vimentin and Fascin-1 (3-4).  
Interestingly, enhanced cellular EMT promotion has also been correlated with increased 
levels of reactive oxygen species (ROS), a byproduct of oxidative phosphorylation, as well as 
essential cellular processes. However, in healthy cells, ROS levels adhere to a carefully regulated 
homeostatic balance (5). High ROS has been associated with DNA damage, further promoting 
genomic instability typically observed within cancer cells (6). Excessive and sustained ROS 
levels promote oxidative damage, especially prevalent in the mitochondria, thus impairing the 
metabolic functions of the mitochondria. These sequence of events have been linked to 
mitochondrial release of apoptotic and necrotic factors leading to increased cellular death. In this 
study, mitochondrial dysfunction due to ROS has been implicated in cancer progression and 
corroborates reported findings with regards to mitochondrial biogenesis and mitophagy (7-8).  
Recent research has shown that the mitochondria and endoplasmic reticulum (ER) have a 
particularly striking inter-relationship. Organelles frequently communicate with each other and 
require crosstalk to maintain cellular homeostasis. Non-lethal ER dysfunction may play a role in 
impacting the mitochondrial morphology, calcium storage, and transport, as well as the level of 
mitochondrial and metabolic dysfunction that occurs in cells (15). In particular, Mitofusion 2 has 
been shown to facilitate direct contact interactions between the mitochondria and the ER to 
support calcium transportation and organelle morphology (16).  
Furthermore, cell cycle has been previously reported to be widely dysregulated in cells 
chronically treated with Gefitinib (3). Dysregulation of cell cycle is a hallmark of cancer and is 
often mediated by genomic instability. Genomic volatility and damage are linked to induction of 
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a physiological transformation characterized as senescence. Senescence is a natural cellular 
process where cells lose the capability to continue dividing, which is induced by the DNA 
damage response and is tightly associated with aging. Interestingly, activation of a single 
oncogene or repression of a tumor suppressor can potentially trigger senescence, as a 
physiological fail safe to prevent cancer. However, cancer cells often possess adaptive 
mechanisms that enable bypass of senescence regardless of the level of genomic damage and 
instability (17-20).  
While development of novel anti-cancer agents is an important scientific endeavor, it is 
somewhat inevitable that cancer cells will eventually develop resistance to even the most novel 
therapies; which is partially due to the dynamic nature of the tumor microenvironment, as well as 
inherent flexibility and adaptive potential of cancer cells. This necessitates a better understanding 
of the cellular mechanisms that promote resistance within tumors in order to allow for the 
development of long-lasting and effective therapies.  
This study is a logical extension of previous work that screened multiple lung cancer cell 
lines utilizing established tyrosine kinase inhibitors, namely Gefitinib and Erlotinib. Based on 
published observations, H1650 lung cancer provided the best response with low levels of 
Gefitinib treatment. Additionally, the previous work also illustrated increased ROS levels and 
decreased mitochondrial respiration that resulted due to chronic Gefitinib exposure (3). In this 
study we found that chronic Gefitinib exposure caused an increase in oxidative damage which 
ultimately results in mitochondrial, endoplasmic reticulum and excessive DNA damage that is 
not mitigated through the natural cellular fail-safe, senescence.   
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2 RESULTS 
2.1 Validating Gefitinib Resistance in H1650 Lung Cancer Cells.  
H1650, a human non-small cell lung carcinoma (NSCLC) cell line that contains a kinase 
dependent EGFR mutation, DelE746-A750 an in-frame exon 19 deletion, was subject to 
approximately 16 to 20 weeks of chronic dose-escalating Gefitinib treatment. Previously 
identified EMT markers were immunoblotted to confirm and validate further occurrence of 
reported resistance phenotype (3). Mesenchymal markers, namely; Vimentin, Fascin-1, and 
CD44 exhibited an expected upregulation in protein expression in Gefitinib resistant cells (Gef) 
Figure 1: Validating Gefitinib Resistance in H1650 lung cancer cells.  
A, Western blot validated the epithelial to mesenchymal protein expression shift that had previously been 
established in chronic Gefitinib treated H1650. NT refers to no treatment and Gef refers to chronic Gefitinib 
treatment that resulted in a Gefitinib resistant phenotype. B and C, Upregulation of Vimentin and downregulation of 
E-cadherin were further confirmed using confocal microscopy. Quantification of confocal images was done using 
pixel intensity computation and an unpaired t test where n=3. * corresponds to p < 0.05. Additionally, error bars 
specify means + standard error. AU denotes arbitrary units. D, ROS levels were measured at two time points 30 and 
60 minutes using 2', 7’-dichlorodihydrofluorescein diacetate (H2DCFDA) a fluorescence indictor for ROS species. 
Fluorescence was measured at Ex/Em 495/525. Both non-treated H1650 and Gef H1650 were stimulated with 
hydrogen peroxide (a cellular stress known to induce ROS) and Mito-Tempo (a mitochondria- specific antioxidant 
known to deplete ROS). * corresponds to p < 0.05 calculated using an unpaired t test where n=8. In addition, error 
bars specify means + standard error.   
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while epithelial markers, E-cadherin and Keratin 19 were significantly downregulated (Figure 1, 
A). These results were further confirmed using florescent microscopy (Figure 1, B and C). 
Vimentin plays a key role in mediating EMT and its upregulation is strongly correlated with 
increased cellular motility, as well as an invasive poorer tumor phenotype (3). Conversely, E-
cadherin is reported to be strongly implicated in cellular adhesion. As a result, E-cadherin and 
Vimentin demonstrate opposing expression profiles with implications for motility potential and 
tumor phenotype (4).    
Previous data, also established a striking increase in ROS levels in Gefitinib treated H1650 
(3). Intercellular dihydrofluorescein levels were measured as a readout of oxidative stress in both 
non-treated (NT) and Gefitinib resistant H1650 cells. It was observed that resistant cells 
exhibited dramatically high levels of ROS relative to non-treated cells (Figure 1, D). 
Furthermore, when non-treated and resistant cells were treated with Mito-Tempo, a 
mitochondria- specific antioxidant, resistant and untreated isogenic H1650 cells exhibited a 
remarkable decrease in ROS levels (Figure 1, D).  
Additionally, cells were exposed to hydrogen peroxide, a known ROS stress inducer. 
Interestingly, non-treated cells exhibited increased ROS levels relative to Gefitinib resistant cells 
(Figure 1, D). A similar striking trend was observed when cells exposed to hydrogen peroxide 
were incubated with Mito-Tempo. Gefitinib resistant cells exhibited almost a complete recovery 
of ROS levels, while non-treated H1650 were not significantly attenuated (Figure 1, D). This 
data suggests that Gef-treated cells have become accustomed to heightened ROS levels, and as a 
result, are more responsive upon exposure to Mito-Tempo. Taken together, these data are 
consistent with previously published observations with respect to chronic Gefitinib treatments 
and resistant phenotypes in H1650 lung cancer cells (3).    
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2.2 Chronic Gefitinib Treatment Instigates Aberrant Mitochondrial Biogenesis and 
Metabolism.  
Next, we set out to investigate potential effects of excessive ROS accumulation. Given 
previous reports of decreased cellular oxygen consumption rate (OCR) and ATP levels in 
chronic Gefitinib treated cells, we then investigated whether alterations of mitochondrial 
biogenesis may contribute to diminished metabolic activity (3). Mitochondrial biogenesis refers 
to the fission and fusion of mitochondria, a phenomenon that is commonly promoted by cellular 
Figure 2: Chronic Gefitinib Treatments Instigates Aberrant Mitochondrial Biogenesis 
and Metabolism.  
A, Chronic Gefitinib treatment on H1650 cells resulted in altered expression of mitochondrial biogenesis 
factors. Quantification of western blot protein expression was done using ImageJ densitometry and an unpaired t test 
where n=3. * corresponds to p < 0.05. Additionally, error bars specify means + standard error. B, Chronic Gefitinib 
treatment did not affect mRNA levels of mitochondrial biogenesis factors. Quantification was done using an 
unpaired t test where n=4. C, Downregulation of Drp1 and upregulation of Mfn1 were further demonstrated using 
microscopy in normal H1650 and Gefitinib resistant H1650. D, Mitochondrial membrane potential was measured 
using the Tetramethylrhodamine ethyl ester fluorescent red-orange dye that accumulates in active negatively 
charged mitochondria. Fluorescence was measured at Ex/Em 549/575. *** corresponds to p < 0.001 and was 
calculated using an unpaired t test where n=12. Additionally, error bars specify means + standard error. E, 
Microscopy using Mitotracker Green revealed Gef exhibited tubular elongated mitochondria as opposed to NT 
single circular mitochondria.  
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stress and remodeling. Mitochondrial fusion results in fewer mitochondria that are larger in size, 
while the opposite is true for mitochondrial fission (9, 10). Biochemical analysis revealed that 
mitochondrial fission factors exhibited a global decrease under chronic Gefitinib treatment 
(Figure 2, A and C).  Mitochondrial fission factors; Dynamin related protein 1 (Drp1), 
Mitochondrial fission factor (MFF) and Mitochondrial fission 1 protein (Fis1), have been 
reported as critical factors for maintaining mitochondrial homeostasis during cellular stress, 
typically by regulation of new mitochondria, development and removal of damaged ones (9, 10, 
12). However, mitochondrial fusion factors failed to demonstrate a consistent trend. Optic 
Atrophy 1 protein (also called Opa1) was significantly decreased under chronic Gefitinib 
treatment (Figure 2, A and C). Opa1 is responsible for mitochondrial fusion, cristae structure and 
most importantly oxidative phosphorylation or the production of cellular ATP (21). Therefore, 
decreased Opa1 expression in Gef-treated cells is consistent with previously reported ATP 
reduction in these resistant cells. Interestingly, Mitofusion proteins 1 and 2 exhibited an opposite 
trend in Gef cells. The expression of Mitofusion 1 was significantly increased suggesting that 
mitochondrial fusion was increased in Gefitinib resistant cells (Figures 2, A and C). Conversely, 
Mitofusion 2 expression was decreased in Gef cells (Figure 2, A and C). Interestingly, 
Mitofusion 2 has been implicated in the additional role of mediating direct interaction between 
mitochondria and the endoplasmic reticulum (15, 16). Therefore, a loss of Mitofusion 2 
expression may suggest that communication between the mitochondria and ER is attenuated in 
Gefitinib resistant cancer cells. 
Furthermore, using Tetramethylrhodamine ethyl ester, a florescent label for active 
mitochondria, we observed that mitochondrial membrane potential was significantly decreased in 
Gefitinib resistant cells (Figure 2, D). This data suggest that chronic Gefitinib treatment results in 
8 
increased levels of inactive or depolarized mitochondria, which is consistent with reduced ATP 
levels and oxygen consumption (3). Additionally, chronic Gefitinib treatment appeared to impact 
mitochondrial morphology. Non-treated H1650 cells exhibited numerous single circular 
mitochondria while chronic Gefitinib treatment resulted in fewer mitochondria that were large, 
tubular, and elongated in morphology (Figure 2, E). Taken together, this data demonstrates that 
chronic Gefitinib treatment results in impaired mitochondrial biogenesis, morphology and 
metabolic function.  
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2.3 Chronic Gefitinib Treatment Promotes Endoplasmic Reticulum Dysfunction. 
Given the close connection between mitochondria and ER, as well as Gefitinib instigated 
mitochondrial defects of chronic Gefitinib treatment, we subsequently evaluated the ER in 
greater detail. The expression of several ER molecules associated with protein chaperoning, 
folding, stress and calcium were assessed. Calnexin, an ER calcium dependent protein chaperone 
was significantly decreased in Gef cells relative to non-treated controls (Figure 3, A and C). As 
an ER transmembrane chaperone protein, Calnexin is ubiquitously expressed in all ER 
containing cells. Decreased Calnexin expression has been reported to correlate with increased 
Figure 3: Chronic Gefitinib Treatment Promotes Endoplasmic Reticulum Dysfunction.  
A, Gefitinib resistant H1650 resulted in an increased expression of Calcium related protein, calreticulin, as 
well as increased expression of ER stress marker, ERp72. Quantification of western blot protein expression was 
done using ImageJ densitometry and an unpaired t test where n=3. * corresponds to p < 0.05. Additionally, error 
bars specify means + standard error. B, Chronic Gefitinib treatment did not affect mRNA levels of ER targets of 
interest. Quantification was done using an unpaired t test where n=4. C, Biochemical data exhibiting the 
downregulation of Calnexin and upregulation of Calreticulin and ERp72 was further demonstrated using microscopy 
in normal H1650 and Gefitinib resistant H1650. D, Microscopy using ER tracker Red revealed increased cellular 
distribution and localization of the ER in Gef. E, Intercellular calcium content of Gef was measured using the 
fluorescent calcium binding Fluo-8 dye. Fluorescence was measured at Ex/Em 490/525. *** corresponds to p < 
0.001 and was calculated using an unpaired t test where n=5. Additionally, error bars specify means + standard 
error.  
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protein misfolding and therefore activation of the ER stress response via; unfolded protein 
response (UPR) (22). This suggests that a reduction of Calnexin expression correlates with an 
increase in ER stress in chronic Gefitinib treated cells. Protein chaperone, Calreticulin, and ER 
stress- response protein, ERp72, were significantly increased in Gef cells (Figure 3, A and C). 
Calreticulin, which plays a role similar to Calnexin with respect to cellular calcium sensing, is 
responsible for protein quality control in the ER, with additional roles binding to and inactivating 
calcium. Previous studies have reported that Calreticulin overexpression is correlated with 
decreased mitochondrial membrane potential which is consistent with our results (Figure 2, D) 
(23). Interestingly, ER enzyme protein disulfide isomerase, PDI, and receptor binding cancer 
antigen 1, RCAS1, did not exhibit significant changes although they are often associated with 
cancer phenotypes and cancer progression (Figure 3, A-C) (24, 25). Additionally, imaged ER 
morphological changes indicate that altered ER morphology may be a secondary consequence of 
chronic Gefitinib treatment. Non-treated H1650 cells exhibited tight central cellular distribution 
of ER while chronic Gefitinib treatment resulted in ER morphology that was enlarged, loose and 
closely localized to the cell membrane (Figure 3, D). 
Calcium provides a direct link between the ER and mitochondria, and as would be 
expected it tightly associated with cellular metabolism. Using Fluo-8, a fluorescent calcium 
binding dye, we observed that intercellular calcium levels of Gefitinib treated cells were 
significantly diminished in comparison to non-treated cells (Figure 3, E). Typically, cancer is 
associated with hypercalcemia. However, it has been reported that certain drug treatments can 
induce a hypocalcemic phenotype. In normal cells, calcium is tightly regulated and is an integral 
part of metabolic activity and ATP production (15, 16, 27). Thereby suggesting that a reduction 
of calcium could lead to an increase in mitochondrial depolarization. Additionally, the dramatic 
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reduction in cellular calcium under chronic Gefitinib treatment is consistent with observed 
decrease in Calnexin expression (Figure 3, A and C). Taken together, these data are in agreement 
with mitochondrial perturbation, supporting the notion that chronic Gefitinib treatment induces 
metabolic dysfunction through ER and mitochondrial distress mechanisms.  
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2.4 Gefitinib Resistance Results in Increased DNA Damage and Perturbed Cell Cycle.  
The effects of reactive oxygen species have been well documented. Nucleic acid damage 
is a highly accepted effect of ROS (5, 6). Based on the foregoing information, we assessed the 
level of DNA damage in the non-treated and Gefitinib resistant lung cancer cells. In agreement 
with previous studies, we observed that both single strand and double strand DNA damage were 
significantly increased in Gefitinib resistant cells (Figure 4, A-C) (5, 6). Typically, cellular DNA 
damage activates the senescent response pathway, degrading the ability of genetically damaged 
cells to divide and proliferate (17).  
Figure 4: Gefitinib Resistance Results in Increased DNA Damage and Perturbed Cell 
Cycle.  
A and B, Single cell gel electrophoresis demonstrated increased comet tails in Gef, corresponding to both 
increased single strand and double strand DNA damage. Quantification of single cell gel electrophoresis images was 
done using comet assay tail measurement software and an unpaired t test. * corresponds to p < 0.05. Additionally, 
error bars specify means + standard error. C, Additional microscopy further confirmed an increase in double strand 
DNA damage in Gef cells. D, Cellular senescence was detected by measuring β-Galactosidase activity at a pH of 6. 
*** corresponds to p < 0.001 and was calculated using an unpaired t test where n=10. Additionally, error bars 
specify means + standard error. E, Western blot analysis revealed a striking downregulation of phospho and total Rb 
as well as a dramatic increase in DNA damage markers phospho and total γH2AX. Quantification of western blot 
protein expression was done using ImageJ densitometry and an unpaired t test where n=3. * corresponds to p < 0.05. 
Additionally, error bars specify means + standard error. F, Chronic Gefitinib treatment did not affect mRNA levels 
of yH2AX, a DNA damage marker. Quantification was done using an unpaired t test where n=4.     
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However, we observed that β- Galactosidase activity in Gefitinib resistant cells was severely 
reduced, indicating, circumvention of senescence checkpoint and continued cell proliferation 
(Figure 4, D).  
Due to the lack of the senescent pathway activation, we analyzed a variety of cell cycle 
and senescence markers. We confirmed reduced expression of Retinoblastoma protein (Rb), p21 
and p27 (Figure 4, E). Rb is a well-known tumor suppressor that is responsible for evaluating 
cells before they are allowed to progress through the cell cycle G1 checkpoint into S phase (28). 
Absence of Rb has been associated with decreased thyroid cancer patient survival (29). 
Similarly, the loss of G1 checkpoint cyclin dependent kinase (CDK) inhibitors p21 and p27 has 
also been correlated with both poor tumor and drug resistant phenotypes. Loss of these cell cycle 
proteins results in aberrant and uncontrolled cell growth (30, 31). Previous experiments have 
shown that Gefitinib resistant H1650 demonstrated abnormal overpopulated G2 cell cycle phase 
(3).  Western blot data further confirmed the increase in DNA damage through the use of DNA 
damage marker γH2AX (Figure 4, C, E and F) (32). Overall, this data demonstrates that chronic 
Gefitinib treatment results in substantially increased levels of DNA damage and dysregulated 
cell cycle resulting in an increase in proliferation and a bypass of senescence damage control 
response pathway.       
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2.5 In-Vivo Characterization of Gefitinib Resistant H1650 Cells.  
Chronic Gefitinib treatment, in-vitro, resulted in mitochondrial and ER dysfunction as 
well as increased levels of DNA damage and cell cycle dysregulation. We, therefore, extended 
these observations by employing an in-vivo nude mice model. Approximately 1 million NT or 
Gef cells were combined with Matrigel and subcutaneously implanted into the flanks of Athymic 
nude mice to develop tumors in-vivo. Tumors were harvested after 3 weeks of growth, and the 
expression of cytokeratin 7 provided positive confirmation that the excised tumors were 
implanted H1650 lung cancer cells (Figure 5, E) (33). Likewise, the presence of Vimentin a key 
EMT marker was confirmed and upregulated in implanted Gefitinib resistant tumors (Figure 5, 
C).  
 
Figure 5: In-Vivo Characterization of Gefitinib Resistant H1650 Cells. 
A and B, NT and Gef H1650 cells were subcutaneously implanted into the flanks of Athymic nude mice. 
Tumors were harvested after 3 weeks of growth and measured. C, The presence of Vimentin was used as a cellular 
marker to identify Gefitinib resistance. Western blot analysis also revealed a continuation of the gene expression 
pattern observed in-vitro. D, H & E staining revealed nuclear damage in tumors composed of non-treated H1650 
while tumors composed of Gefitinib resistant H1650 exhibited an increase in lymphocyte infiltration. E, 
Immunohistochemical staining for cytokeratin 7, a lung cancer marker, provided positive confirmation that the 
tissue excised was lung cancer (H1650).  
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There was no significant difference in tumor size between the implanted non-treated and 
Gefitinib resistant cells (Figure 5, A and B). Surprisingly, Gefitinib resistant tumors were slightly 
smaller in size than the non-treated implanted cancer cells, which may suggest that the perturbed 
phenotype of the drug resistant tumor may play important roles in resistance rather than actual 
tumor size. Tumor morphology, as measured by H&E staining, revealed an interesting 
phenotypic difference between the NT and Gef tumors. NT tumors exhibited an increase of 
nuclear damage as well as an influx of nuclei. The latter of which suggests increased 
proliferative capacity. High proliferative capacity of NT cells is not surprising, given the fact that 
the NT tumors were composed of normal cancer cells devoid of drug treatment. Interestingly, 
Gefitinib resistant tumors displayed an influx of lymphocyte infiltration which may contribute to 
observed decreased tumor size (Figure 5, D). Given the primary effect of Gefitinib, which targets 
aberrant EGFR- driven proliferation, the drug appeared to maintain its major function. However, 
chronic Gefitinib treatment results in secondary cellular and genetic consequences in a subset of 
the treated cell population, giving rise to a cellular phenotype that may be akin to cancer stem 
cells. Cancer stem cells are reported to have a dynamic phenotype that drives tumor development 
and progression (34). Suggesting that, this residual subset may be responsible for instigating the 
drug resistant phenotype.  
16 
3 DISCUSSION 
This study focused on elucidation of phenotypic changes that result due to chronic targeted 
cancer therapies. Here we employed a tyrosine kinase inhibitor, Gefitinib, treatment in H1650 
lung cancer cells. Gefitinib resistance was confirmed using previously established EMT markers, 
with specific focus on canonical Vimentin and E-cadherin expression profiles (Figure 1, A-C). 
We observed that chronic Gefitinib treatment correlated with increased cellular ROS levels, and 
amplified oxidative stress (Figure 1, D). As would be expected, an increase in oxidative stress 
resulted in DNA damage as well as cell cycle dysregulation, and aberrant morphology and 
function of cell organelles. For example, significant changes to mitochondrial morphology, 
biogenesis and metabolism were observed. Chronic Gefitinib treatment resulted in the presence 
of fewer mitochondria that were enlarged in appearance, while also increasing the number of 
depolarized or inactive mitochondria as measured by a decrease in the mitochondrial membrane 
potential capacity (Figure 2, D and E). Metabolic cellular capacity is also tied to the endoplasmic 
Figure 6: Schematic Diagram of Gefitinib Resistance in H1650 
Lung Cancer Cells. 
 This diagram illustrates the three prong secondary effects that result due to 
chronic Gefitinib treatment.  
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reticulum, and chronic Gefitinib treatment resulted in decreased intercellular calcium levels, 
which may account for the increased presence of depolarized mitochondria (Figure 3, E). 
Supportively, chronic Gefitinib treatment gave rise to both an increase in ER stress protein, 
ERp72, as well as calcium inactivating protein, Calreticulin (Figure 3 A and C). 
A more established effect of oxidative stress is increased DNA damage. In healthy cells 
DNA damage activates the DNA damage response pathway which either induces DNA repair or 
removes the cell from the cell cycle and limits its proliferative capacity by instigating a senescent 
phenotype (35). However, chronically Gefitinib treated cells are able to bypass the senescence 
pathway and continue proliferating despite their excessive levels of DNA damage (Figure 4, A-
D). Additionally, for proliferation to be successful in the presence of DNA damage, a 
dysregulated cell cycle is required. Significant downregulation of cell cycle checkpoint markers 
Rb, p27 and p21 were observed in Gef cells relative to non-treated control cells (Figure 4, E). 
Expanding these experiments in-vivo yielded paradoxical results (Figure 5, C). In-vitro, 
we observed dysregulated cell cycle as well as the ability to bypass cellular senescence in 
chronically Gefitinib treated cells. However, tumors derived from Gefitinib resistant cells did not 
exhibit increased proliferative capacity (Figure 5, A and B). Rather the tumor phenotypes and 
volume suggested that the sizes of Gefitinib resistant tumors were not as significant as their 
observed cellular aberration. Additionally, staining for proliferation marker Ki67 revealed that 
Gef tumors displayed significantly increased positive staining for Ki67 relative to NT (Data not 
shown). Ki67 is often used as a pathological prognostic marker to determine the proliferative 
capacity of a tumor. Increased levels of Ki67 are reported to be associated with poor tumor 
phenotype and decreased patient survival (36). This data appears to be in direct conflict with our 
reported in-vitro observations. It is important to caution that conclusions drawn from our in-vivo 
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data are limited at best, due to the small number of mice utilized (n=4). Further studies are 
necessary to determine the full extent of Gefitinib resistance in-vivo. Likewise, expanding the 
project to include additional cancer cell lines and targeted agents in addition to tyrosine kinase 
inhibitors would be critical to interpret and generalize our observed phenomena. Furthermore, 
given that H1650 cells are a low proliferating and relatively unaggressive, it may prove 
beneficial to use well established aggressive cancer cell lines to develop resistance and 
recapitulate the xenograft experiment.  
Additionally, repeat of the xenograft experiment would benefit from inclusion of 
Gefitinib treatment administration in order to test responsiveness or resistance, in-vivo. We 
previously performed this set of experiments using a small number of mice (n=2), and thus no 
significant conclusions were deduced (Data not shown).  
In conclusion, the foregoing findings suggest that chronic exposure to targeted therapy 
may contribute to development of a toxic tumor microenvironment, and cancer cell adaptation 
that may negatively affect patient outcome. Identification and characterization of specific cellular 
perturbations due to chronic cancer therapies may provide useful clues for development of 
improved therapies or diagnostics.            
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4 MATERIALS AND METHODS  
Reagents. Gefitinib (Iressa) was purchased from Tocris Bioscience. Gapdh, β-Actin and 
Cytokeratin 7 primary antibodies were purchased from Santa Cruz Biotechnology, Ki-67 and 
Pink1 primary antibodies were purchased from Abcam. All other primary antibodies were 
purchased from Cell Signaling. Rabbit and mouse secondary antibodies for western blot were 
purchased from Cell Signaling. Rabbit and mouse Alexa Fluor secondary antibodies for 
microscopy were purchased from Invitrogen.    
Development of Gefitinib Resistant H1650. Normal, non-treated H1650 cells were exposed to 
chronic dose-escalating Gefitinib treatment for 16 to 20 weeks. Cells were maintained under 
Gefitinib selection. 
Western Blot (SDS-Page). Reducing buffered cell or tissue lysates were run on gels of either 
8, 10 or 12%, before being transferred onto nitrocellulose membranes. Membranes were blocked 
with 5% powdered milk dissolved in TBST (tris-buffered saline and tween 20) and then probed 
with antibodies of interest and imaged using film development or GE Healthcare Lifesciences 
Amersham Gel Imager. 
Confocal Microscopy. Cells were seeded onto 25 mm circular coverslips, fixed with 4% 
paraformaldehyde, permeabilized with 0.1% Triton, blocked with 5% BSA (bovine serum 
albumin) dissolved in PBS (phosphate buffered saline) then probed for antibodies of interest. 
Coverslips were mounted using Prolong Gold Antifade Mountant with DAPI (purchased from 
Molecular Probes by Life Technologies). Slides were imaged using a 710 Zeiss confocal 
microscope via indirect immunofluorescence. 
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ROS Measurement. ROS was measured using a H2DCFDA ROS Detection Assay Kit 
(purchased from Molecular Probes Life Technologies). ROS levels were detected by measuring 
fluorescence (excitation/ emission at 485/535) using a Tecan Infinite M1000. 
Quantitative Real Time PCR. RNA was isolated using the RNeasy Kit (purchased from 
Qiagen). cDNA was generated using the RT2 First Strand Kit (purchased from Qiagen) and 
loaded into custom PrimePCR plates containing targets of interest (purchased from Bio-Rad 
Laboratories). Data was acquired using a Bio-Rad CFX96 C1000 thermal cycler.  
β-Galactosidase Staining. Senescence was measured using the Senescence β-Galactosidase 
Staining Kit (purchased from Cell Signaling Technologies). Cells were imaged using an Inverted 
Olympus Optical Light Microscope.  
TMRE Mitochondrial Potential Assay. Mitochondrial membrane potential was quantified in 
live cells using the TMRE Mitochondrial Potential Assay (purchased from Abcam). 
Mitochondrial potential levels were detected via tetramethylrhodamine, ethyl ester labeling and 
quantified by measuring fluorescence (excitation/ emission at 549/575) using a Tecan Infinite 
M1000 as well as fluorescent microscopy using an Inverted Olympus Optical Light Microscope.   
Calcium Assay. Intracellular calcium flux was measured using the Rhod-4 Calcium Assay 
Kit (purchased from Abcam). Intracellular calcium levels were detected using the florescent 
Rhod-4 dye and quantified by measuring fluorescence (excitation/ emission at 540/590) using a 
Tecan Infinite M1000.     
Subcutaneous Tumor Implantation. Approximately 1 million H1650 normal no treatment 
cells were mixed with Matrigel Matrix (purchased from Corning Incorporated) in a 1:1 ratio. 
This procedure was repeated for Gefitinib resistant H1650 cells. These mixtures were 
subcutaneously injected into the flanks of 12 week old Athymic Nude Mice (purchased from 
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Jackson Laboratory) and allowed to grow for 3 weeks. No treatment H1650 was injected into the 
right flanks and Gefitinib resistant H1650 was injected into the left flanks. 4 mice received tumor 
localized Gefitinib injections (or the corresponding DMSO vehicle injections) 2 weeks after 
initial subcutaneous tumor implantation.     
Hematoxylin and Eosin Staining. Harvested tumor tissue was fixed in 4% formalin at room 
temperature for a minimum of 36 hours before being processed overnight using the Excelsior AS 
Tissue Processor from ThermoFisher Scientific. Processed tissue was embedded in Paraffin 
using the HistoStar Embedding Workstation from ThermoFisher Scientific. Paraffin embedded 
tissue was cut into 5 µm sections using the Leica Manual Rotary Microtome before being fixed 
onto frosted microscope slides. Sections were deparaffinized and rehydrated. Hematoxylin 
staining was approximately 4 minutes long followed by a 2 quick dips in 0.3% acid alcohol. 
Bluing took approximately 10 minutes and was done using running tap water. Eosin staining was 
approximately 2 minutes long followed by dehydration and cover slip application. Images were 
taken using an Olympus Optical Light Microscope.        
Immunohistochemistry. Tissue fixation, processing and sectioning was performed using the 
same procedure as hematoxylin and eosin staining. Sections were deparaffinized and rehydrated 
before undergoing antigen retrieval using sodium citrate buffer. Sections blocked for 1 hour at 
RT. Primary antibodies were applied overnight at 4°C. Dako secondary antibody (purchased 
from Agilient) were applied for 1 hour followed by development using DAB chromogen 
(purchased from Agilient). Sections were counterstained using Hematoxylin followed by 
dehydration and coverslip application. Images were taken using an Olympus Optical Light 
Microscope.  
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Statistical Analysis. Data was expressed as mean + SEM. Statistical Analysis was completed 
using Unpaired Students t-test, one way ANOVA or two way ANOVA in GraphPad Prism 5 
Software. P-values < 0.05 were considered significant. Optical density and fluorescent pixel 
quantification was done using NIH ImageJ software.   
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